Claraphi Advisory Network’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-771
Closed -$223K 227
2022
Q3
$223K Sell
771
-1,094
-59% -$315K 0.12% 166
2022
Q2
$526K Buy
+1,865
New +$499K 0.19% 131
2020
Q2
Sell
-1,441
Closed -$343K 1174
2020
Q1
$343K Buy
+1,441
New +$331K 0.16% 126

Other funds holding VRTX

Claraphi Advisory Network's VRTX Position: Q4 2022 in Review

Claraphi Advisory Network sold out of Vertex Pharmaceuticals (VRTX) in Q4 2022, closing a stake of 771 shares — an estimated $223K sold.

Claraphi Advisory Network first reported a position in VRTX in Q1 2020 and held it in 3 quarters. The position peaked at $526K in Q2 2022. 1,222 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

  • Claraphi Advisory Network reported no remaining Vertex Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Claraphi Advisory Network sold 771 Vertex Pharmaceuticals shares in Q4 2022, an estimated $223K.
  • Claraphi Advisory Network first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 3 quarters.
  • Claraphi Advisory Network's Vertex Pharmaceuticals position peaked at $526K in Q2 2022.
  • 1,222 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Claraphi Advisory Network's 13F filing for Q4 2022, filed 14 Feb 2023.